Hysteroscopy.
Conditions
Interventions
Intervention 1: Intervention group: In patients of this group, 2 capsules of 500 mg evening primrose oil ( Abidi Pharmaceutical Company) are placed in the posterior fornix of the vagina by the residen
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Menopausal women or women of reproductive age with no history of normal vaginal delivery (NVD) Closure of the cervix
Exclusion criteria
Exclusion criteria: Women with cervical structural abnormalities and a history of cervical insufficiency Women with Müller malformations Women with a history of conization Women with any contraindications to EPO or misoprostol (EPO or misoprostol contraindications such as seizures, asthma, high blood pressure, glaucoma, etc.) Women who have a history of failed hysteroscopy or D&C due to severe cervical stenosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time to reach the required dilatation (3 to 7 mm). Timepoint: From the start of the operation until reaching the required expansion. Method of measurement: Clinical. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cervical rupture. Timepoint: Immediately after the patient regains consciousness. Method of measurement: Clinical observations.;Perforation of the uterus. Timepoint: Immediately after the patient regains consciousness. Method of measurement: Clinical observations.;Side effects. Timepoint: Immediately after the patient regains consciousness. Method of measurement: Clinical observations. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarkhondeh Ghavampour
Qazvin University of Medical Sciences
Outcome results
None listed